With media solemnly spotlighting the passing of the 200,000 mark in deaths attributed to COVID-19 in the United States, a physicians assocation has a question.
“Why is the death rate about 75 percent lower in many countries?” asked Dr. Jane Orient, executive director of the Association of American Physicians and Surgeons.
The reference is to a country-based analysis updated Sept. 20 that shows a gap between countries that treat COVID-19 early or prophylactically with hydroxychloroquine and those that, like the U.S., discourage or prohibit its use.
The answer to Orient’s question can be found in a white paper published by the Economic Standard this month titled “Hydroxychloroquine and the Burden of Proof: An Urgent Call to Depoliticize Medicine in the COVID-19 Pandemic.”
“The COVID-19 pandemic struck America nine months before a presidential election, turning basic medical activities like testing and treatment into partisan battlegrounds,” writes Economic Standard Editor-in-Chief Erik Sass in the overview. “No subject has been more distorted than hydroxychloroquine (HCQ), a safe, versatile medicine that has treated hundreds of millions of people for numerous diseases for seven decades.”